1. Scrip

Pfizer Agrees To Roll Back Prices On 40 Drugs, Yielding To Pressure From Trump

 
• By Jessica Merrill

After a conversation with President Trump, CEO Ian Read agreed to cancel price increases on 40 drugs that took effect July 1, to give the administration time to work on its blueprint for improving the health care system.

Trump_Donald_160716_1200x675

Pfizer Inc. CEO Ian Read has agreed to claw back price increases on 40 drugs after a phone conversation with President Donald Trump July 10, in what represents an extraordinary move by a big pharma to yield to pressure from the US president. Pfizer's decision to roll back the recent price increases comes a day after the president publicly shamed Pfizer on Twitter for increasing drug prices.

"Following an extensive discussion with President Trump today, Pfizer's Chairman and CEO Ian Read announced that it will defer the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

AI Is Inevitable, But Useful Only If Solves The Right Problems

 
• By Mandy Jackson

Scrip spoke with executives at artificial intelligence biotech firms and a big pharma company during the recent BIO conference about using AI in ways that add real value to drug development.

Moderna’s Spikevax Wins Pediatric Approval, But With Narrower Label

 
• By Alaric DeArment

The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.